Immatics Reports Interim Clinical Data From ACTengine IMA203 And IMA203CD8 TCR-T Monotherapies Targeting PRAME In An Ongoing Phase 1 Trial
Portfolio Pulse from Benzinga Newsdesk
Immatics has reported interim clinical data from its ongoing Phase 1 trial of ACTengine IMA203 and IMA203CD8 TCR-T monotherapies targeting PRAME. The company has not disclosed the specifics of the data.
November 08, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Immatics has reported interim clinical data from its ongoing Phase 1 trial, which could potentially impact the company's stock price depending on the nature of the results.
The news is directly related to Immatics' ongoing clinical trial. The impact on the stock price will depend on the nature of the results, which have not been disclosed. Positive results could boost the stock price, while negative results could lead to a decline.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100